Dr. David L. Barker, Ph.D., has served on our Board of Directors since May 2010, and as Chairman of our Board of Directors since August 2016. Dr. Barker also serves as a director of AmideBio, Singular Genomics Systems, and Aspen Neuroscience.
He is also a scientific advisor to MiNDERA Corp. and Luna DNA. He served as Vice President and Chief Scientific Officer at Illumina, Inc., from 2000 to 2007, and on the Illumina scientific advisory board until May 2016. He was previously on the Boards of NextBio, which was acquired by Illumina in 2013, ProteinSimple, which was acquired by Bio-Techne in 2014, Zephyrus Biosciences, Inc., acquired by Bio-Techne in 2016, IntegenX, acquired by Thermo Fisher Scientific in 2018, and Integrated Diagnostics, acquired by Biodesix in 2018.
Dr. Barker served from 1998 to 2000 as Vice President and Chief Science Advisor at Amersham Biosciences, now part of General Electric. From 1988 to 1998, Dr. Barker held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham.
In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a BS with honors in Chemistry from the California Institute of Technology and a PhD in Biochemistry from Brandeis University.
Albert Luderer has three decades of experience in biotechnology, with special focuses on technology, business development and commercialization.
Dr. Luderer is CEO and board director at personalized diagnostics company Integrated Diagnostics. He also serves as CEO and board director of molecular therapeutics and imaging company Indi Molecular.
Dr. Luderer previously served as president and CEO of BioTrove, a venture-backed molecular biological tools company that was acquired by Life Technologies. Additionally, Dr. Luderer was CEO of venture-backed therapeutics company Light Sciences and president and COO of bioMérieux, Inc.
Senior management positions at Dianon Systems (LabCorp), Boehringer Mannheim (Roche), and Corning round out Dr. Luderer’s experience in the industry. He earned his PhD from Rutgers University, where he was a National Science Foundation predoctoral fellow, and performed postgraduate work in immunology at Jefferson Medical College.
Christopher J. Twomey has served on our board of directors since July 2018. Since August 2013, Mr. Twomey has served as a director and Chairman of the Audit Committee of Tandem Diabetes Care, Inc., a medical device company.
Since March 2006, Mr. Twomey has served as a director and Chairman of the Audit Committee of Senomyx, Inc., a taste technologies company. From March 1990 to June 2007, Mr. Twomey served in various roles of increasing responsibility, including as Senior Vice President, Finance and Chief Financial Officer, at Biosite Incorporated, a medical diagnostics company, until it was acquired by Inverness Medical in 2007. While serving at Biosite, Mr. Twomey was responsible for the Finance, Human Resources, Facilities, and Information Systems departments. From October 1981 to March 1990, Mr. Twomey served as an audit manager for Ernst & Young, LLP. Mr. Twomey also served as a director and Chairman of the Audit Committee of Cadence Pharmaceuticals, Inc., a specialty pharmaceutical company that was acquired by Mallinckrodt plc in 2014. Mr. Twomey received his B.A. in Business Economics from the University of California at Santa Barbara.
Kristiina Vuori has served on our board of directors since June 2019. Since January 2010, Dr. Vuori has served as President of Sanford Burnham Prebys Medical Discovery Institute, or the Institute, a non-profit research organization with major research programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases.
In addition, Dr. Vuori has also held the Pauline and Stanley Foster Presidential Chair at the Institute since January 2010 and served as the Institute’s interim Chief Executive Officer from January 2013 to September 2014, and from September 2017 to present. Since January 1995, Dr. Vuori has served as a Professor at the Institute’s National Cancer Institute designated Cancer Center, an interdisciplinary basic and translational research effort mobilizing over 400 scientists. In addition, from July 2014 to September 2017, Dr. Vuori served on the board of directors of WebMD, and she serves or has served in the past five years on the boards of directors of the American Association for Cancer Research, the California Institute for Regenerative Medicine, and the California Breast Cancer Research Council. Dr. Vuori earned her M.D. and Ph.D. from the University of Oulu, Finland. Our board of directors believes that Dr. Vuori’s experience in biomedical research and as an educator of research scientists, her experience managing a large non-profit research organization, and her various leadership roles qualify her to serve on our board of directors.
Hannah Mamuszka is the founder and Chief Executive Officer of Alva10, an advisory firm focused on creating partnerships between payors and diagnostic companies to increase the value of diagnostic technology, which she founded in March 2016.
From December 2010 to June 2015, she served as Vice President of Business Development and Clinical Strategy at Exosome Diagnostics, Inc., a private company developing liquid biopsy tests. Prior to joining Exosome, Ms. Mamuszka served as Director of Strategic Business Development, Companion Diagnostics at Asuragen, Inc., a private company focused on diagnostics and therapeutics. From January 2005 to January 2010, Ms. Mamuszka served in various director level positions, most recently as Global Director for Pharmaceutical Services, at Oncotech Inc., then by acquisition, at Exiqon A/S. Ms. Mamuszka has also served as an Executive Director of Precision Care Alliance, a non-profit focused on policy reform to enable diagnostic development. Ms. Mamuszka has previously held various laboratory positions at ArQule, Inc., Millennium Pharmaceuticals Inc., Organogenesis, Inc. and the National Cancer Institute. Ms. Mamuszka received her BS in neurobiology and physiology from the University of Maryland at College Park and her MS in molecular biology from Harvard University.
Yvonne Linney founded Linney BioConsulting, an advisory and strategy development firm in the life sciences industry, in January 2019. Dr. Linney has served as a strategic advisor to General Automation Laboratory Technologies (GALT) since November 2019, SRI International since June 2019, the California Life Sciences Institute since March 2019, and to Tag.bio, Inc. since January 2019.
From January 2017 to November 2018, Dr. Linney served as the Chief Executive Officer of Transcriptic Inc. (now Strateos, Inc.), a private company that developed a robotic cloud laboratory platform, where she had previously served as Chief Operating Officer since October 2015. Dr. Linney also served on Transcriptic’s Board of Directors from December 2016 to November 2018. In addition, from November 2006 to January 2015, Dr. Linney served as Executive Vice President and General Manager, Life Sciences at Agilent Technologies, Inc., a public life sciences and diagnostics company. Prior to joining Agilent, Dr. Linney served as Director of Molecular Diagnostics and Global Strategic Marketing at Bayer Diagnostics (now part of Siemens Healthcare) from 2005 to 2006 and Senior Director, Marketing and Product Management at Caliper Life Sciences from 2003 to 2005. Dr. Linney also served as Director of Genomics at Amersham International (now GE Healthcare) from 1993 to 2003. Dr. Linney holds a BS in microbiology and virology from Warwick University, UK, and a Ph.D. in genetics from Leicester University, UK.